Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Old sedative, new trick: amobarbital may shield the heart during bypass surgery

NCT ID NCT06757868

Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This trial investigates whether a single dose of amobarbital, an older sedative, can protect the heart muscle in adults undergoing cardiac surgery with a heart-lung machine. Researchers will measure how quickly the heart restarts after bypass and track recovery times and heart damage markers. The goal is to see if this inexpensive drug can improve surgical outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
amobarbital
What this could lead to
If it works, this could point toward a simple, low-cost way to protect the heart during surgery and speed up recovery.
What could go wrong
This is a small, early-stage trial with 80 people, so results may not apply to everyone. Amobarbital is a sedative and may cause side effects like drowsiness or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Feb 2025

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age range: 18-65 years old, undergo elective cardiac surgery with extracorporeal circulation. * ASA II-III; * surgical duration is 3-6 hours; * Sign the informed consent form Exclusion Criteria: * BMI less than 18 kg/m2 or greater than 30 kg/m2; * Individuals with a history or potential history of drug abuse or alcohol dependence; * Preoperative use of sedatives or analgesics; * Individuals with severe liver and kidney dysfunction; * Individuals who are allergic or potentially allergic to barbiturates; * Patients with coagulation dysfunction, endocrine disorders, or other conditions that affect hemodynamic status; * Participated in other clinical studies in the past 3 months; * The researchers believe that participants who are not suitable to participate in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiopulmonary bypass are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiopulmonary bypass

Contacts and locations

Locations

  • Tongji hospital

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.